middl
east
respiratori
syndrom
coronaviru
merscov
caus
agent
sever
respiratori
diseas
associ
human
infect
death
countri
sinc
approv
treatment
merscov
infect
although
combin
lopinavir
ritonavir
interferon
beta
lpvrtvifnb
current
evalu
human
kingdom
saudi
arabia
show
remdesivir
rdv
ifnb
superior
antivir
activ
lpv
rtv
vitro
mice
prophylact
therapeut
rdv
improv
pulmonari
function
reduc
lung
viral
load
sever
lung
patholog
contrast
prophylact
lpvrtvifnb
slightli
reduc
viral
load
without
impact
diseas
paramet
therapeut
lpvrtvifnb
improv
pulmonari
function
reduc
viru
replic
sever
lung
patholog
thu
provid
vivo
evid
potenti
rdv
treat
merscov
infect
coronaviru
cov
famili
propens
emerg
new
host
often
caus
novel
sever
diseas
middl
east
respiratori
syndrom
coronaviru
merscov
discov
caus
agent
sever
respiratori
syndrom
kingdom
saudi
arabia
ksa
sinc
caus
least
case
death
global
merscov
endem
camel
zoonot
reservoir
host
evid
infect
go
back
least
year
camel
middl
east
perhap
east
africa
continu
seed
human
infect
may
requir
hospit
especi
age
individu
preexist
comorbid
similar
sever
acut
respiratori
syndrom
cov
sarscov
merscov
spread
countri
via
air
travel
infect
peopl
singl
import
case
caus
outbreak
case
south
korea
recent
case
import
middl
east
contain
result
rapid
implement
public
health
measur
merscov
continu
caus
human
infect
global
thu
list
prioriti
pathogen
pandem
potenti
world
health
organ
coalit
epidem
prepared
innov
cepi
present
approv
treatment
merscov
human
cov
emerg
viral
diseas
typic
effect
treatment
option
treatment
design
approv
diseas
administ
patient
emerg
viral
syndrom
empir
base
limit
clinic
laboratori
data
multipl
us
food
drug
administr
fda
approv
therapi
evalu
antivir
activ
merscov
vitro
includ
lopinavir
lpv
ritonavir
rtv
interferon
beta
ifnb
lpv
human
immunodefici
viru
proteas
inhibitor
usual
combin
rtv
increas
lpv
halflif
inhibit
cytochrom
although
antivir
activ
lpv
merscov
report
vero
cell
concentr
caus
reduct
replic
ec
studi
report
complet
inact
similar
rtv
contrast
studi
evalu
antivir
activ
type
type
ii
interferon
report
ifnb
potent
interferon
ec
iuml
reduc
merscov
replic
vitro
vivo
studi
assess
therapeut
efficaci
lpvrtv
ifnb
merscov
publish
thu
far
perform
common
marmoset
modest
improv
clinic
outcom
note
human
merscov
patient
two
publish
case
report
describ
conflict
result
use
combin
lpvrtv
pegyl
interferon
ribavirin
one
two
patient
surviv
end
random
control
trial
miracl
trial
aim
conclus
determin
lpvrtvifnb
improv
clinic
outcom
merscov
patient
initi
thu
far
enrol
patient
ksa
remdesivir
rdv
broadspectrum
antivir
nucleotid
prodrug
potent
vitro
antivir
activ
divers
panel
rna
virus
ebola
viru
ebov
marburg
merscov
sarscov
respiratori
syncyti
viru
rsv
nipah
viru
niv
hendra
viru
mechan
rdv
antimerscov
activ
like
prematur
termin
viral
rna
transcript
shown
biochem
assay
use
recombin
ebov
niv
rsv
polymeras
primari
human
lung
epitheli
cell
cultur
rdv
potent
antivir
circul
contemporari
human
cov
sarscov
ec
merscov
ec
relat
zoonot
bat
cov
recent
report
therapeut
rdv
improv
diseas
outcom
reduc
viral
load
sarscovinfect
mice
sinc
similar
studi
perform
merscov
gener
transgen
mous
human
merscov
receptor
dipeptidyl
peptidas
delet
carboxylesteras
improv
pharmacokinet
nucleotid
prodrug
better
approxim
drug
exposur
profil
human
show
rdv
provid
superior
antivir
activ
merscov
vitro
vivo
compar
lpvrtvifnb
addit
rdv
therapeut
treatment
significantli
reduc
pulmonari
patholog
thu
provid
vivo
evid
potenti
rdv
treat
merscov
infect
rdv
ifnb
superior
antivir
activ
lpv
rtv
util
recombin
merscov
engin
express
report
nanoluciferas
mersnluc
vitro
antivir
activ
assay
ensur
report
viru
behav
similarli
wt
merscov
first
demonstr
mersnluc
wildtyp
wt
merscov
emc
strain
replic
similar
level
absenc
drug
treatment
similarli
suscept
antivir
activ
rdv
wt
ec
mersnluc
ec
human
lung
epitheli
cell
line
supplementari
fig
data
agreement
wt
mer
jordan
strain
ec
report
warren
et
al
thu
futur
report
viru
data
repres
wt
merscov
perform
parallel
antivir
assay
cell
mersnluc
compar
lpv
rtv
ifnb
rdv
fig
supplementari
fig
similar
previou
report
rdv
show
potent
inhibit
merscov
replic
ec
observ
cytotox
select
index
si
ec
cc
fig
contrast
respect
ec
valu
gener
lpv
rtv
cc
valu
fig
c
thu
si
lpv
rtv
respect
combin
lpv
rtv
lpv
rtv
molar
ratio
current
evalu
miracl
trial
antivir
activ
lpv
rtv
ec
similar
lpv
alon
ec
p
wilcoxon
matchedpair
sign
rank
test
suggest
effect
larg
driven
lpv
fig
found
potent
inhibit
merscov
ifnb
ec
intern
unit
iu
ml
fig
cc
valu
iuml
si
togeth
data
demonstr
rdv
ifnb
superior
vitro
antivir
activ
compar
lpv
rtv
rtv
significantli
enhanc
antivir
activ
lpv
vitro
ifnb
activ
improv
combin
lpvrtv
cell
cultur
medium
human
plasma
differ
concentr
type
protein
directli
affect
level
biolog
avail
free
drug
unbound
protein
complic
comparison
drug
level
respect
system
address
issu
util
compar
equilibrium
dialysi
ced
determin
differ
free
unbound
drug
human
plasma
cell
cultur
medium
reveal
maxim
plasma
concentr
c
max
human
plasma
amount
free
unbound
lpv
lpv
fb
contain
cell
cultur
medium
thu
combin
lpv
rtv
fix
molar
ratio
combin
increas
concentr
ifnb
antivir
activ
lpvrtvifnb
combin
ec
iuml
indistinguish
ifnb
alon
ec
iuml
p
wilcoxon
matchedpair
sign
rank
test
fig
data
suggest
observ
vitro
antivir
activ
lpvrtvifnb
combin
merscov
domin
ifnb
lpvrtv
use
clinic
relev
concentr
merscov
mous
model
test
nucleotid
prodrug
unlik
human
mice
high
level
serum
esteras
carboxylesteras
drastic
reduc
stabil
rdv
mice
requir
efficaci
studi
perform
mice
better
approxim
pharmacokinet
drug
exposur
profil
human
merscov
infect
standard
laboratori
mice
prevent
due
differ
human
mous
dipeptidyl
peptidas
entri
receptor
merscov
enabl
test
rdv
mice
bred
mice
mice
harbor
modifi
human
via
residu
result
mice
indistinguish
viru
replic
pathogenesi
mice
infect
merscov
supplementari
fig
prophylact
rdv
diminish
merscov
replic
diseas
use
new
mous
model
sought
determin
prophylact
rdv
could
amelior
merscov
diseas
shown
fig
prophylact
rdv
mgkg
bid
administ
day
prior
infect
significantli
diminish
merscovinduc
weight
loss
mice
infect
p
twoway
anova
tukey
multipl
comparison
test
plaqueform
unit
pfu
p
twoway
anova
tukey
multipl
comparison
test
compar
similarli
infect
vehicletr
anim
moreov
rdv
administ
prior
infect
also
prevent
mortal
p
mantelcox
test
administ
lethal
dose
ie
pfu
fig
contrast
vehicletr
anim
lung
hemorrhag
significantli
reduc
p
twoway
anova
tukey
multipl
comparison
test
rdv
prophylaxi
fig
importantli
rdv
prophylaxi
significantli
reduc
viru
lung
titer
log
p
p
twoway
anova
sidek
multipl
comparison
test
day
post
infect
dpi
p
twoway
anova
sidek
multipl
comparison
test
fig
corrobor
viral
antigen
label
lung
tissu
section
fig
rdv
prophylaxi
reduc
featur
ali
american
thorac
societi
at
issu
consensu
document
defin
paramet
tool
accur
translat
small
anim
model
acut
lung
injuri
ali
human
condit
use
at
lung
injuri
score
system
design
quantit
histopatholog
featur
ali
fig
blindli
score
field
hematoxylin
eosin
stain
lung
tissu
section
mice
fig
follow
featur
neutrophil
alveolar
interstiti
space
hyalin
membran
proteinac
debri
fill
air
space
alveolar
septal
thicken
compar
control
mice
at
lung
injuri
score
significantli
reduc
rdvtreat
mice
p
mannwhitney
test
infect
pfu
merscov
approach
statist
signific
p
mannwhitney
test
infect
higher
viru
dose
pfu
fig
fig
also
show
exampl
quantit
patholog
featur
normal
healthi
mockinfect
control
mice
fig
alveolar
air
space
free
debri
inflammatori
cell
wall
ie
septa
alveolar
sac
thin
facilit
effici
ga
exchang
rare
neutrophil
circul
seen
capillari
within
alveolar
septa
air
space
contrast
vehicletr
merscovinfect
anim
viral
dosag
group
fig
multipl
histolog
featur
ali
includ
notabl
immun
cell
infiltr
alveolar
septa
result
septal
wall
thicken
scatter
degener
die
cell
proteinac
debri
air
space
result
capillari
leakag
organ
hyalin
membran
neutrophil
alveolar
septa
well
air
space
interestingli
earli
hyalin
membran
ie
thin
pink
materi
line
alveoli
note
vehicletr
anim
infect
lower
dose
merscov
fig
left
develop
hyalin
membran
ie
thick
pink
materi
line
alveoli
observ
vehicletr
anim
infect
higher
dose
viru
fig
right
importantli
air
space
rdvtreat
anim
infect
lower
dose
merscov
fig
fig
importantli
kinet
gene
express
target
organ
merscov
lung
similar
mice
supplementari
fig
similarli
singl
dose
ifnb
significantli
induc
sustain
express
p
twoway
anova
sidek
multipl
comparison
test
interferon
gammainduc
protein
serum
strain
mice
supplementari
fig
thu
observ
expect
isg
respons
blood
lung
tissu
mice
follow
ifnb
treatment
evalu
lpvrtvifnb
prophylaxi
could
improv
outcom
mice
infect
pfu
merscov
compar
vehicl
oral
propylen
glycol
ethanol
subcutan
pb
three
differ
treatment
scenario
includ
lpvrtvifnb
high
hed
ifnb
lpvrtvifnb
low
hed
ifnb
ifnbhigh
alon
h
ed
ifnb
fig
prophylact
rdv
vehicl
includ
control
sinc
isg
express
peak
h
ifnb
administr
supplementari
fig
initi
ifnb
dose
h
prior
merscov
infect
maxim
potenti
antivir
effect
similar
previou
studi
rdv
mgkg
bid
vehicl
administ
subcutan
everi
h
obtain
exposur
mice
similar
observ
human
dose
level
frequenc
lpvrtv
oral
daili
ifnb
subcutan
everi
day
chosen
mirror
miracl
trial
unlik
rdvtreat
mice
fig
vehicl
lpvrtvifnb
ifnb
alon
prevent
weight
loss
fig
fact
anim
administ
ifnb
alon
lost
significantli
weight
vehicl
p
lpvrtvifnb
high
p
low
p
twoway
anova
tukey
multipl
comparison
test
group
fig
dpi
rdv
treatment
reduc
viru
lung
titer
log
reduct
vehicl
median
pfulob
rdv
median
pfulob
fig
lpvrtvifnb
low
treat
modestli
reduc
median
pfulob
compar
vehicl
median
pfulob
p
twoway
asterisk
indic
statist
signific
differ
p
determin
twoway
anova
tukey
multipl
comparison
test
b
percent
surviv
cohort
surviv
analysi
mantelcox
test
p
n
per
group
note
c
lung
hemorrhag
score
scale
normal
pink
healthi
lung
complet
dark
red
lung
dpi
n
dpi
remain
anim
plot
asterisk
indic
statist
signific
differ
p
determin
twoway
anova
tukey
multipl
comparison
test
merscov
lung
titer
n
dpi
remain
anim
asterisk
indic
statist
signific
differ
p
determin
twoway
anova
sidek
multipl
comparison
test
c
box
encompass
percentil
line
median
whisker
repres
rang
e
hematoxylin
nuclei
blue
immunostain
merscov
antigen
brown
lung
tissu
section
dpi
photo
taken
magnif
black
bar
indic
scale
imag
repres
mice
group
shown
anova
sidek
multipl
comparison
test
fig
upon
measur
pulmonari
function
wholebodi
plethysmographi
wbp
found
rdv
prophylaxi
improv
pulmonari
function
fig
b
p
twoway
anova
sidek
multipl
comparison
test
interestingli
anim
receiv
ifnbalon
significantli
wors
pulmonari
function
companion
group
later
time
post
infect
dpi
p
twoway
anova
tukey
multipl
comparison
test
determin
initi
time
dose
level
would
affect
outcom
ifnb
group
perform
similar
studi
administ
ifnb
lower
dose
ie
hed
h
prior
infect
supplementari
fig
alter
ifnb
dose
time
administr
improv
outcom
fig
modest
improv
viru
titer
seen
lpvrtvifnb
note
observ
taken
togeth
prophylact
lpvrtvifnb
caus
modest
reduct
lung
viral
load
one
two
studi
minim
impact
diseas
metric
ifnb
alon
impact
viru
replic
exacerb
diseas
therapeut
rdv
reduc
merscov
replic
patholog
stringent
assess
therapeut
potenti
rdv
lpvrtvifnb
better
model
human
scenario
merscov
patient
like
would
initi
treatment
infect
perform
seri
therapeut
efficaci
studi
mice
initi
follow
treatment
mice
infect
pfu
merscov
dpi
rdv
vehicl
lpvrtvifnb
low
human
equival
lpvrtvifnb
high
human
equival
vehicl
dose
rout
amount
frequenc
similar
prophylact
studi
therapeut
rdv
substanti
reduc
bodi
weight
loss
p
twoway
anova
tukey
multipl
comparison
test
fig
b
lung
hemorrhag
dpi
fig
p
oneway
anova
kruskalw
test
similarli
rdv
treatment
significantli
reduc
viru
lung
titer
dpi
vehicl
median
pfu
lobe
rdv
median
pfulob
p
oneway
anova
kruskalw
test
fig
corrobor
viral
antigen
label
lung
tissu
section
fig
similar
therapeut
rdv
lpvrtvifnb
improv
pulmonari
function
therapeut
antivir
efficaci
studi
describ
fig
use
wbp
assess
pulmonari
function
fig
contrast
vehicletr
anim
rdvtreat
anim
reduc
flow
rate
expir
volum
p
twoway
anova
sidek
multipl
comparison
test
penh
p
twoway
anova
sidek
multipl
comparison
test
surrog
measur
airway
resistanceobstruct
fig
similarli
rpef
fraction
expir
peak
expiratori
flow
reach
indic
bronchoconstrict
return
baselin
rdvtreat
anim
dpi
p
twoway
anova
sidek
multipl
comparison
test
yet
remain
suppress
vehicletr
anim
unlik
prophylact
studi
fig
therapeut
lpv
rtvifnb
low
improv
pulmonari
function
compar
vehicl
significantli
reduc
penh
p
twoway
anova
tukey
multipl
comparison
test
baselin
level
rpef
dpi
p
twoway
anova
tukey
multipl
comparison
test
fig
therapeut
lpvrtvifnb
fail
reduc
weight
loss
lung
hemorrhag
viru
titer
regimen
appear
provid
improv
pulmonari
function
similar
therapeut
rdv
therapeut
rdv
lpvrtvifnb
diminish
sign
ali
quantit
lung
patholog
therapeut
treat
anim
fig
lung
tissu
section
dpi
blindli
evalu
score
featur
ali
use
three
differ
complementari
approach
fig
show
reduc
ali
rdv
treatment
although
sporad
apoptot
cell
alveolar
septal
wall
thicken
mock
driven
immun
cell
infiltr
observ
lung
mice
treat
therapeut
rdv
air
space
remain
predominantli
free
cellular
debri
inflammatori
cell
similar
mockinfect
anim
fig
contrast
multipl
patholog
featur
typic
ali
note
vehicl
group
rdv
lpvrtv
vehicl
well
lpvrtvifnb
low
high
includ
alter
alveolar
architectur
due
pneumocyt
degener
death
numer
inflammatori
cell
septa
alveolar
air
space
neutrophil
air
space
proteinac
debri
air
space
organ
hyalin
membran
fig
use
at
ali
score
tool
describ
fig
found
rdv
therapi
significantli
p
oneway
anova
kruskalw
test
decreas
lung
injuri
score
fig
complementari
histolog
tool
quantit
featur
diffus
alveolar
damag
dad
patholog
hallmark
ali
found
therapeut
rdv
reduc
dad
score
p
oneway
anova
kruskalw
test
fig
sinc
degre
cell
death
appear
correl
protect
efficaci
quantit
level
cleav
lung
tissu
section
antibodi
label
wide
accept
marker
apoptosi
regulatori
enzym
whose
cleavag
activ
drive
program
cell
death
use
definien
softwar
suit
obtain
unbias
quantit
data
show
rdv
treatment
significantli
reduc
level
cleav
antigen
p
oneway
anova
kruskalw
test
fig
thu
use
three
complementari
blind
approach
obtain
similar
data
show
therapeut
rdv
reduc
histolog
featur
ali
emerg
viral
diseas
caus
signific
global
pandem
eg
hiv
influenza
smallpox
epidem
eg
sarscov
devast
outbreak
eg
ebov
merscov
cov
metagenom
studi
wild
anim
reveal
great
divers
virus
host
even
identifi
virus
similar
current
past
epidem
strain
bat
thu
broadspectrum
therapi
effect
known
epidem
zoonot
strain
like
seed
futur
emerg
potenti
diminish
epidem
diseas
today
diminish
futur
outbreak
current
fdaapprov
treatment
human
cov
infect
upon
emerg
sarsand
merscov
patient
administ
offlabel
antivir
eg
ribavirin
lpv
rtv
immunomodul
eg
corticosteroid
interferon
ifnb
singl
agent
combin
attempt
amelior
sever
diseas
outcom
limit
success
without
random
control
trial
determin
efficaci
difficult
due
patient
treatment
variabl
well
lack
appropri
match
control
although
recent
metaanalysi
model
suggest
interferon
treatment
improv
clinic
outcom
merscov
patient
differ
protein
ident
concentr
complic
translat
vitro
antivir
activ
vivo
therapeut
efficaci
although
ec
lpv
merscov
ec
fall
within
maximum
c
max
minimum
c
min
level
observ
human
plasma
biolog
avail
fraction
unbound
protein
respect
system
compar
accur
translat
vitro
activ
potenti
vivo
efficaci
exampl
trough
level
c
min
total
unbound
protein
free
lpv
women
hiv
differ
lpv
still
highli
activ
effect
sinc
ec
fall
unbound
protein
free
c
min
togeth
data
argu
level
free
biolog
activ
lpv
achiev
human
well
exert
robust
antivir
effect
merscov
replic
cell
cultur
system
thu
micromolar
ec
observ
lpv
merscov
coupl
protein
bind
insuffici
level
free
lpv
plasma
like
respons
modest
antivir
effect
lpvrtvifnb
prophylaxi
minim
impact
diseas
therapeut
administr
mous
model
contrast
human
equival
dose
rdv
demonstr
efficaci
mice
infect
sarsand
merscov
nonhuman
primat
infect
ebov
thu
demonstr
suitabl
pkpd
relationship
interferon
use
treat
multipl
viral
infect
sinc
ifnb
shown
potent
merscov
compar
antivir
activ
multipl
type
type
ii
interferon
vero
cell
ifnb
select
use
miracl
trial
mirror
miracl
trial
deliv
ifnb
subcutan
everi
day
fail
reduc
merscov
viral
load
appear
exacerb
diseas
mice
sought
understand
result
found
littl
experiment
congruenc
among
report
detail
prophylact
therapeut
efficaci
type
interferon
anim
model
merscov
falzarano
et
al
demonstr
coupl
ribavirin
initi
h
post
infect
improv
outcom
rhesu
macaqu
reduc
viral
copi
number
lung
tissu
treatment
effect
infecti
viru
titer
bronchoalveolar
lavag
fluid
mice
deliv
lung
tissu
adenovir
transduct
intranas
ifnb
given
merscov
infect
reduc
lung
titer
although
peak
lung
titer
model
approxim
two
order
magnitud
lower
current
transgen
model
thu
may
easili
treat
util
common
marmoset
model
merscov
pathogenesi
controversi
one
studi
detail
sever
respiratori
diseas
yet
anoth
report
similarli
mild
diseas
among
mock
merscovinfect
anim
marmoset
chan
et
al
explor
therapeut
potenti
lpvrtv
ifnb
small
number
anim
use
per
group
lack
timematch
viral
load
sampl
unexpect
earli
mortal
lpv
group
made
result
data
difficult
interpret
nevertheless
studi
note
demonstr
type
interferon
exert
antivir
effect
merscov
vivo
given
subcutan
ifn
alpha
rhesu
macaqu
intranas
ifnb
adenoviru
model
inabl
reduc
merscov
titer
improv
outcom
ifn
describ
may
due
inher
differ
anim
acut
lung
injuri
ali
human
well
defin
set
clinic
paramet
ie
acut
onset
diffus
bilater
infiltr
xray
ratio
partial
pressur
arteri
oxygen
inspir
oxygen
evid
elev
pulmonari
arteri
pressur
etc
measur
mice
requir
special
procedur
equip
train
readili
avail
research
moreov
anim
model
ali
typic
fail
recapitul
patholog
featur
observ
human
like
due
differ
underli
anatomi
physiolog
immunolog
genet
complex
comorbid
typic
associ
hospit
ali
patient
eg
diabet
kidney
liver
diseas
etc
exampl
mice
distinctli
differ
lobar
composit
less
branch
conduct
airway
human
rest
respiratori
rate
far
exceed
human
bpm
mice
bpm
human
differ
amount
neutrophil
circul
mice
human
address
issu
american
thorac
societi
at
creat
tool
simplifi
translat
mous
model
ali
human
condit
includ
quantit
hallmark
ali
tissu
section
employ
complementari
quantit
histolog
assess
tool
diffus
alveolar
damag
dad
patholog
hallmark
ali
human
at
ali
dad
histolog
assess
tool
describ
along
quantit
cell
death
via
cleav
antigen
label
show
rdv
therapi
reduc
ali
initi
dpi
therefor
evid
sever
complementari
histolog
approach
demonstr
rdv
provid
superior
protect
ali
compar
lpvrtvifnb
remdesivir
rdv
broadspectrum
antivir
potent
vitro
efficaci
multipl
genet
unrel
rna
virus
rdv
demonstr
vivo
efficaci
ebov
nonhuman
primat
led
inclus
clinic
studi
evalu
effect
rdv
treatment
acut
ebola
viru
diseas
evd
well
evd
survivor
prolong
viral
shed
sarscov
studi
rdv
provid
similar
evid
merscov
diminish
weight
loss
improv
pulmonari
function
reduc
viru
replic
prophylact
therapeut
rdv
kinet
sarsor
merscov
replic
diseas
mice
substanti
acceler
compar
human
viru
replic
lung
peak
dpi
lung
mice
infect
sarscov
merscov
infect
progress
mortal
recoveri
dpi
depend
viru
dose
therefor
therapeut
window
treat
mice
prior
peak
viru
replic
day
contrast
merscov
replic
human
respiratori
tract
peak
day
onset
symptom
diseas
cours
resolv
progress
death
day
thu
window
therapeut
administr
onset
symptom
prior
peak
viru
replic
differ
human
experiment
infect
mice
therapeut
rdv
observ
decreas
merscov
pathogenesi
signific
reduct
viral
titer
yet
therapeut
treatment
complet
abrog
diseas
addit
hightit
viru
inoculum
rdv
unabl
prevent
mortal
loss
pulmonari
function
although
significantli
reduc
viral
load
result
similar
obtain
sarscov
therapeut
treatment
initi
peak
viru
titer
lung
damag
fail
improv
outcom
yet
significantli
reduc
viral
titer
similar
observ
recent
report
neutral
monoclon
antibodi
fail
reduc
sever
lung
diseas
patholog
clinic
diseas
administ
day
merscov
infect
marmoset
sinc
diseas
result
sarsand
merscov
infect
driven
viru
host
immun
respons
factor
depend
stage
diseas
progress
earli
initi
antivir
therapi
andor
holist
combin
therapi
like
need
diminish
viru
replic
immunopatholog
andor
promot
repair
restor
pulmonari
homeostasi
ongo
futur
studi
aim
determin
merscov
capabl
gener
resist
rdv
vitro
whether
mutat
spectra
similar
obtain
mhv
sarscov
shift
ec
valu
summari
provid
vivo
evid
potenti
util
rdv
treat
merscov
patient
overal
work
suggest
rdv
may
improv
diseas
outcom
covinfect
patient
serv
protect
health
care
worker
area
endem
merscov
prove
valuabl
prevent
futur
epidem
event
novel
cov
emerg
futur
studi
design
primari
goal
studi
compar
prophylact
therapeut
efficaci
rdv
combin
lpvrtv
ifnb
first
assess
antivir
efficaci
cytox
human
lung
cell
line
compar
appropri
vehicl
control
experiment
condit
vitro
perform
sextupl
unless
otherwis
state
antivir
assay
repeat
four
time
per
drug
second
evalu
vivo
efficaci
prophylact
rdv
compar
vehicl
two
differ
dose
merscov
new
transgen
mous
model
merscov
pathogenesi
improv
pharmacokinet
nucleotid
prodrug
perform
two
addit
prophylact
studi
compar
rdv
vehicl
lpvrtvifnb
ifnbalon
vehicl
third
assess
therapeut
efficaci
treatment
regimen
mous
model
merscov
pathogenesi
includ
ifnb
arm
studi
perform
twice
lung
histolog
assess
perform
blind
manner
addit
perform
singl
therapeut
efficaci
studi
lethal
dose
merscov
vivo
efficaci
studi
design
mirror
ongo
miracl
human
clinic
trial
evalu
combin
lpvrtvifnb
studi
intend
gener
data
requir
justifi
test
nonhuman
primat
collect
inform
futur
human
clinic
trial
mice
ageand
sexmatch
randomli
assign
group
infect
treatment
exclus
criteria
vivo
studi
follow
given
mous
unexpectedli
lose
weight
infect
viru
lung
titer
log
lower
mean
group
indic
infect
ineffici
data
relat
mous
censor
anim
care
ethic
statement
efficaci
studi
perform
anim
biosafeti
level
facil
unc
chapel
hill
work
conduct
protocol
approv
institut
anim
care
use
committe
unc
chapel
hill
iacuc
protocol
accord
guidelin
set
associ
assess
accredit
laboratori
anim
care
us
depart
agricultur
viru
vitro
studi
merscov
report
viru
express
nanoluciferas
employ
mersnluc
mersnluc
stock
deriv
molecular
clone
electropor
vero
cell
atcc
isol
viru
harvest
cultur
supernat
briefli
dna
fragment
af
encod
mersnluc
cdna
genom
ligat
creat
fulllength
cdna
use
templat
vitro
transcript
fulllength
genom
rna
electropor
cell
yield
recombin
viru
stock
result
stock
passag
twice
vero
gener
work
stock
pfuml
studi
wildtyp
merscov
compar
antivir
efficaci
studi
deriv
emc
infecti
clone
describ
obtain
work
stock
titer
pfuml
vivo
studi
util
mous
adapt
merscov
passag
clone
mer
mer
amino
acid
code
chang
well
singlenucleotid
chang
utr
larg
delet
viru
clonal
isol
gener
serial
passag
merscov
mice
passag
mice
viru
plaqu
purifi
clone
expand
two
time
vero
cell
obtain
work
stock
work
stock
pfuml
creat
viru
collect
medium
optimem
gibco
fetal
clone
ii
serum
product
hyclon
antibioticantimycot
gibco
nonessenti
amino
acid
gibco
compound
formul
vitro
studi
remdesivir
rdv
lopinavir
lpv
ritonavir
rtv
solubil
dmso
provid
gilead
scienc
inc
recombin
human
interferon
beta
ifnb
protein
purchas
r
system
iumg
compar
standard
solubil
steril
water
recommend
vitro
efficaci
cytotox
cell
determin
viru
replic
kinet
rdv
suscept
similar
among
wildtyp
wt
merscov
emc
mersnluc
perform
compar
antivir
assay
human
lung
epitheli
cell
line
kindli
provid
dr
chien
tseng
univers
texa
medic
branch
maintain
dmem
gibco
fetal
bovin
serum
fb
hyclon
antibioticantimycot
aa
gibco
briefli
h
prior
infect
cell
plate
cellswel
twentyfour
hour
prior
infect
cultur
medium
exchang
fresh
medium
cell
infect
wt
emc
mersnluc
multipl
infect
moi
h
cell
wash
dose
respons
rdv
dilut
twofold
step
media
dmem
fb
dmem
aa
ad
duplic
cell
incub
co
h
media
well
collect
assay
viru
product
plaqu
assay
vero
cell
briefli
vero
cellswel
seed
sixwel
plate
follow
day
medium
remov
serial
dilut
sampl
ad
per
plate
dilut
incub
h
well
overlay
dmem
fetal
clone
serum
aa
agaros
three
day
plaqu
enumer
gener
plaqueml
valu
ic
valu
defin
graphpad
prism
graphpad
better
understand
antivir
activ
rdv
lpv
rtv
ifnb
combin
lpvrtv
lpvrtvifnb
perform
efficaci
cytotox
assay
human
lung
epitheli
cell
cell
plate
describ
infect
merscov
express
nanoluciferas
mersnluc
sextupl
moi
h
presenc
dose
respons
drug
describ
h
infect
viru
remov
cultur
rins
medium
fresh
medium
ad
contain
dilut
drug
rdv
ie
stock
mm
serial
dilut
dmso
twofold
increment
obtain
tenpoint
dilut
seri
human
ifnb
r
system
iuml
similarli
dilut
pb
lpv
mm
stock
rtv
mm
stock
similarli
dilut
dmso
although
variou
amount
stock
compound
ad
directli
media
obtain
top
four
dilut
tenpoint
curv
model
antivir
effect
fix
dose
combin
lpvrtv
use
treat
hiv
perform
antivir
assay
fix
combin
lpvrtv
weight
weight
ratio
molar
ratio
lpvrtv
combin
serial
dilut
dmso
twofold
increment
mixtur
stock
ad
directli
media
similar
obtain
top
four
concentr
studi
repeat
independ
experi
model
lpvrtv
combin
ifnb
first
perform
compar
equilibrium
dialysi
ced
determin
lpv
fb
contain
cell
cultur
medium
gave
amount
free
ie
unbound
protein
lpv
maximum
concentr
attain
human
plasma
c
max
ie
combin
dose
respons
human
ifnb
fix
concentr
lpvrtv
molar
ratio
lopinavir
ritonavir
base
human
plasma
equival
maxim
concentr
lpv
determin
ced
ie
thu
studi
aim
determin
maxim
amount
lpv
attain
human
provid
addit
synergist
antivir
effect
combin
ifnb
studi
perform
cell
cultur
medium
contain
fb
dmso
constant
condit
h
post
infect
hpi
viru
replic
quantifi
spectramax
molecular
devic
via
nanoluciferas
assay
nanoglo
promega
valu
replic
well
per
condit
averag
compar
control
gener
percent
inhibit
valu
drug
dilut
ic
valu
defin
graphpad
prism
graphpad
concentr
decreas
viral
replic
use
uvtreat
mersnluc
inhibit
vehicl
alon
inhibit
control
measur
cytotox
cell
expos
drug
dilut
control
efficaci
studi
absenc
viru
infect
h
exposur
cell
viabil
determin
celltiterglo
assay
promega
quantit
spectramax
similar
data
obtain
least
three
independ
experi
formul
vivo
studi
rdv
solubil
mgml
vehicl
contain
sodium
salt
water
hcl
naoh
ph
lpv
mgml
rtv
mgml
solubil
vehicl
contain
propylen
glycol
ethanol
ratio
lpv
rtv
held
weight
weight
studi
herein
recombin
mous
ifnb
protein
purchas
r
system
iumg
calibr
murin
ifnbeta
intern
standard
vivo
studi
reconstitut
pb
anim
merscov
bind
human
receptor
dipeptidyl
peptidas
gain
entri
cell
two
residu
bind
interfac
mous
ortholog
prevent
infect
mice
recent
develop
mous
model
merscov
mutat
mous
via
crispr
thu
human
receptor
render
mice
suscept
merscov
infect
serum
carboxylesteras
mice
drastic
reduc
rdv
stabil
thu
vivo
studi
must
perform
mice
genet
delet
stock
jackson
laboratori
order
perform
vivo
efficaci
studi
rdv
merscov
mice
gener
human
mice
defici
express
jackson
laboratori
stock
number
briefli
mous
rederiv
use
oocyt
result
heterozyg
mice
cross
mice
gener
mice
homozyg
delet
heterozyg
allel
result
offspr
genotyp
bred
gener
founder
homozyg
merscov
pathogenesi
mice
determin
pathogenesi
merscov
similar
parent
line
perform
pathogenesi
studi
newli
creat
line
similar
number
n
male
femal
mice
randomli
assign
infect
group
mice
anaesthet
mixtur
ketaminexylazin
intranas
infect
either
pfu
mer
viru
collect
medium
monitor
morbid
mice
weigh
daili
dpi
mice
lost
start
weight
human
sacrif
isofluoran
overdos
better
understand
magnitud
merscov
replic
typic
metric
diseas
infect
femal
mice
mer
viru
collect
medium
done
monitor
morbid
mice
weigh
daili
subset
cohort
randomli
assign
pulmonari
function
measur
wholebodi
plethysmographi
wbp
data
scienc
intern
daili
dpi
anim
kill
isofluran
overdos
lung
score
lung
hemorrhag
inferior
right
lobe
frozen
viral
titrat
via
plaqu
assay
describ
lung
hemorrhag
gross
patholog
phenotyp
readili
observ
nake
eye
driven
degre
viru
replic
color
lung
chang
pink
dark
red
larg
left
lobe
place
buffer
formalin
store
week
histolog
section
analysi
lung
section
hematoxylin
eosin
stain
well
merscov
antigen
primari
antibodi
sera
mice
vaccin
merscov
nucleocapsid
antigen
stain
perform
anim
histopatholog
laboratori
medicin
core
unc
interferon
beta
pharmacodynam
studi
gener
pharmacokinet
pharmacodynam
pkpd
relationship
ifnb
subcutan
administ
mous
ifnb
r
system
weekold
male
femal
mice
human
equival
dose
mice
calcul
base
recommend
dose
strategi
betaseron
human
ifnb
million
intern
unit
miu
kg
everi
day
human
dose
multipli
order
get
mous
equival
dose
miukg
g
mous
g
mous
base
bodi
surfac
area
first
compar
human
equival
dose
ifnb
cohort
n
mice
h
post
treatment
five
mice
per
group
human
euthan
plasma
snapfrozen
peripher
blood
mononuclear
cell
pbmc
isol
place
trizol
ls
thermo
fisher
store
analysi
second
compar
respons
human
equival
dose
ifnb
ie
miukg
g
mous
g
mous
mice
n
ensur
mous
line
respond
similarli
h
post
treatment
mice
human
euthan
plasma
pbmc
isol
store
note
addit
lung
isol
h
post
treatment
store
rnalat
thermo
fisher
analysi
total
rna
isol
pbmc
use
zymo
research
directzol
rna
mini
kit
lung
tissu
homogen
trizol
thermo
fisher
total
rna
isol
similarli
pbmc
respons
ifnb
treatment
pbmc
quantit
qrtpcr
classic
interferon
stimul
gene
mx
dynaminlik
gtpase
taqman
assay
thermo
fisher
use
taqman
fast
viru
master
mix
thermo
fisher
gene
express
compar
signal
housekeep
gene
dehydrogenas
gapdh
thermo
fisher
fold
chang
mock
time
post
treatment
calcul
method
monitor
induct
interferon
induc
protein
express
quantit
level
mous
ifngamma
induc
protein
plasma
via
elisa
invitrogen
prophylact
vivo
efficaci
studi
drug
studi
mice
lost
start
weight
weigh
twice
subject
addit
visual
check
day
clinic
sign
hunch
eas
mobil
lethargi
etc
mice
fell
start
weight
immedi
euthan
mortal
defin
unexpectedli
find
mice
dead
cage
sever
prophylact
studi
perform
determin
drug
regimen
could
affect
viru
replic
andor
diseas
progress
initi
studi
compar
rdv
vehicl
briefli
group
male
femal
randomli
assign
group
n
acclim
day
biosafeti
level
treatment
vehicl
see
rdv
mgkg
bid
subcutan
initi
day
prior
infect
merscov
infect
mice
anaesthet
mixtur
ketaminexylazin
intranas
infect
either
pfu
mer
viru
collect
medium
monitor
morbid
mice
weigh
daili
dpi
anim
kill
isofluran
overdos
lung
score
hemorrhag
describ
inferior
right
lobe
frozen
viral
titrat
via
plaqu
assay
describ
larg
left
lobe
place
buffer
formalin
store
week
section
histolog
analysi
lung
section
hematoxylin
eosin
stain
well
merscov
antigen
stain
describ
perform
anim
histopatholog
laboratori
medicin
core
unc
due
increas
variabl
infect
outcom
male
mice
follow
studi
perform
femal
mice
perform
two
prophylact
studi
ascertain
whether
lpvrtvifnb
ifnb
alon
could
affect
viru
replic
diseas
progress
studi
design
mirror
therapeut
efficaci
studi
first
studi
randomli
assign
group
n
femal
mice
compar
vehicl
lpvrtvifnb
ifnb
alon
treatment
initi
one
day
prior
infect
merscov
infect
mice
anaesthet
mixtur
ketaminexylazin
intranas
infect
either
pfu
mer
viru
collect
medium
human
equival
dose
coformul
lpv
mgkg
rtv
mgkg
mlkg
administ
daili
via
oral
gavag
group
receiv
human
equival
dose
ifnb
r
system
miukg
g
mous
g
mous
dose
everi
day
via
subcutan
inject
control
potenti
vehicl
effect
lpvrtvifnb
group
administ
oral
vehicl
propylen
glycol
ethanol
daili
subcutan
inject
pb
everi
day
rdv
mgkg
mlkg
administ
twice
daili
via
subcutan
inject
control
rdv
addit
group
given
subcutan
vehicl
mice
weigh
daili
monitor
morbid
subset
n
cohort
randomli
assign
pulmonari
function
measur
wholebodi
plethysmographi
wbp
data
scienc
intern
daili
dpi
three
anim
per
group
kill
isofluoran
overdos
lung
score
hemorrhag
describ
larg
left
lobe
frozen
viral
titrat
via
plaqu
assay
describ
dpi
anim
kill
process
done
dpi
second
prophylact
studi
design
optim
potenti
effect
ifnb
base
pkpd
studi
describ
given
interferon
stimul
gene
express
peak
h
post
administr
studi
group
receiv
ifnb
treatment
start
treatment
h
prior
infect
everi
day
thereaft
moreov
maxim
potenti
ifn
effect
ifnb
group
util
human
equival
dose
rather
util
human
equival
dose
done
previou
prophylact
studi
randomli
assign
group
femal
mice
compar
vehicl
lpvrtvifnb
low
miukg
g
mous
g
mous
lpvrtvifnb
high
miukg
g
mous
g
mous
ifnb
high
alon
lpvrtv
dose
amount
schedul
similar
previou
studi
control
dose
effect
vehicletr
mice
receiv
oral
vehicl
subcutan
pb
mirror
ifnb
inject
likewis
ifnb
group
receiv
oral
vehicl
mirror
seen
oral
dose
group
similar
previou
studi
rdv
vehicl
administ
control
merscov
infect
perform
exactli
describ
previou
studi
mice
weigh
daili
monitor
morbid
unlik
previou
studi
pulmonari
function
measur
wbp
data
scienc
intern
perform
mice
group
dpi
measur
perform
remain
mice
per
group
n
dpi
three
anim
per
group
kill
isofluoran
overdos
lung
score
hemorrhag
describ
larg
left
lobe
frozen
viral
titrat
via
plaqu
assay
dpi
anim
kill
process
done
dpi
therapeut
vivo
efficaci
studi
headtohead
therapeut
efficaci
studi
compar
rdv
lpvrtvifnb
femal
randomli
assign
treatment
group
n
day
acclim
time
mice
anaesthet
mixtur
ketaminexylazin
intranas
infect
pfu
mer
viru
collect
medium
see
one
day
post
infect
treatment
initi
lpvrtv
group
mice
administ
human
equival
dose
coformul
lpv
mgkg
rtv
mgkg
mlkg
daili
via
oral
gavag
anim
receiv
lpvrtv
also
receiv
mous
ifnb
r
system
everi
day
one
two
dose
via
subcutan
inject
high
ifnb
dose
group
administ
human
equival
dose
miukg
g
mous
g
mous
low
ifnb
dose
group
administ
human
equival
dose
miukg
g
mous
g
mous
control
potenti
vehicl
effect
lpvrtvifnb
group
administ
oral
vehicl
propylen
glycol
ethanol
daili
subcutan
inject
pb
everi
day
rdv
mgkg
mlkg
administ
twice
daili
via
subcutan
inject
control
rdv
addit
group
given
subcutan
vehicl
control
monitor
morbid
mice
weigh
daili
subset
cohort
randomli
assign
pulmonari
function
measur
wbp
data
scienc
intern
daili
dpi
anim
kill
isofluran
overdos
lung
score
hemorrhag
describ
larg
left
lobe
frozen
viral
titrat
via
plaqu
assay
describ
inferior
right
lobe
place
buffer
formalin
store
week
section
histolog
analysi
lung
section
hematoxylin
eosin
stain
well
merscov
antigen
stain
describ
perform
anim
histopatholog
laboratori
medicin
core
unc
acut
lung
injuri
histolog
assess
tool
use
two
differ
complementari
quantit
histolog
tool
determin
antivir
treatment
diminish
histopatholog
featur
associ
lung
injuri
analys
score
perform
board
certifi
veterinari
pathologist
blind
treatment
group
first
tool
lung
injuri
score
system
creat
american
thorac
societi
order
help
quantit
histolog
featur
ali
observ
mous
model
increas
translat
human
condit
blind
manner
chose
three
random
diseas
field
lung
tissu
high
power
score
follow
neutrophil
alveolar
space
none
cell
cell
b
neutrophil
interstiti
space
septa
none
cell
cell
c
hyalin
membran
none
one
membran
membran
proteinac
debri
air
space
none
one
instanc
instanc
e
alveolar
septal
thicken
mock
thick
mock
thick
mock
thick
obtain
lung
injuri
score
per
field
score
ae
put
follow
formula
contain
multipli
assign
vari
level
import
phenotyp
diseas
state
score
x
b
x
c
x
x
e
score
three
field
per
mous
averag
obtain
final
score
rang
includ
second
histolog
tool
quantit
lung
injuri
report
schmidt
et
al
use
tool
quantit
diffus
alveolar
damag
dad
mice
infect
rsv
dad
patholog
hallmark
ali
similar
implement
at
tool
describ
score
three
random
diseas
field
lung
tissu
high
power
follow
blind
manner
absenc
cellular
slough
necrosi
uncommon
solitari
cell
slough
necrosi
focifield
multifoc
foci
cellular
slough
necrosi
uncommon
septal
wall
hyalin
multifoc
field
cellular
slough
necrosi
common
andor
promin
hyalin
membran
score
three
field
per
mous
averag
get
final
dad
score
per
mous
cleav
antigen
quantit
activ
cleav
form
differenti
immunohistochemistri
lung
tissu
section
stain
cleav
antigen
cell
signal
anim
histopatholog
laboratori
medicin
core
unc
unc
translat
patholog
laboratori
tpl
core
stain
slide
scan
aperio
scanscop
xt
leica
biosystem
power
object
camera
resolut
micron
per
pixel
imag
analyz
definien
architect
xd
tissu
studio
version
within
tissu
section
total
area
calcul
singl
cell
detect
initi
base
hematoxylin
stain
nuclei
cell
border
interpol
tissu
studio
cell
score
cleav
caspas
stain
intens
base
linear
scale
low
medium
high
scale
sum
percent
posit
high
medium
stain
graph
studi
tissu
section
diseas
mous
intestin
use
posit
control
